ECA
PRME icon

Elevate Capital Advisors’s Prime Medicine PRME Stock Holding History

Elevate Capital Advisors’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-151,069
Closed -$526K – 91
2026
Q1 		$526K Buy
151,069
+108,403
+254% +$413K 0.34% 54
2025
Q4 		$148K Buy
+42,666
New +$190K 0.1% 78

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
ACM
Alessandra Capital Management Torrance, California $141M AUM
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
KFGK
Keystone Financial Group (Kentucky) Lexington, Kentucky $1.69B AUM 40.17% 1-Year Est. Return

Elevate Capital Advisors's PRME Position: Q2 2026 in Review

Elevate Capital Advisors sold out of Prime Medicine (PRME) in Q2 2026, closing a stake of 151,069 shares — an estimated $526K sold.

Elevate Capital Advisors first reported a position in PRME in Q4 2025 and held it in 2 quarters. The position peaked at $526K in Q1 2026. 63 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Elevate Capital Advisors reported no remaining Prime Medicine position as of Q2 2026 after selling out during the quarter.
  • Elevate Capital Advisors sold 151,069 Prime Medicine shares in Q2 2026, an estimated $526K.
  • Elevate Capital Advisors first reported a position in Prime Medicine in Q4 2025 and held it in 2 quarters.
  • Elevate Capital Advisors's Prime Medicine position peaked at $526K in Q1 2026.
  • 63 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Elevate Capital Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.